MATILDA: A Prospective, Multi Centre, Interventional, Non-comparator, Open Label Study to Demonstrate the Efficacy, Performance and Safety of ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ Non-Adhesive Dressings in the Management of Surgical and Traumatic Wounds

Sponsor
ConvaTec Inc. (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05632276
Collaborator
(none)
100
1
6.8

Study Details

Study Description

Brief Summary

A prospective, multi centre, interventional, non-comparator, open label study to demonstrate the efficacy, performance and safety of ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ Non-Adhesive dressings in the management of surgical and traumatic wounds

Condition or Disease Intervention/Treatment Phase
  • Device: ConvaFoam
N/A

Detailed Description

A prospective, multi centre, interventional, non-comparator, open label study to demonstrate the efficacy, performance and safety of ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ Non-Adhesive dressings in the management of surgical and traumatic wounds for up to 4 weeks

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
A 4-week device intervention to demonstrate the efficacy, performance and safety of ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ Non-Adhesive dressings in the management of surgical and traumatic woundsA 4-week device intervention to demonstrate the efficacy, performance and safety of ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ Non-Adhesive dressings in the management of surgical and traumatic wounds
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Prospective, Multi Centre, Interventional, Non-comparator, Open Label Study to Demonstrate the Efficacy, Performance and Safety of ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ Non-Adhesive Dressings in the Management of Surgical and Traumatic Wounds
Anticipated Study Start Date :
Jan 31, 2023
Anticipated Primary Completion Date :
Jul 28, 2023
Anticipated Study Completion Date :
Aug 25, 2023

Arms and Interventions

Arm Intervention/Treatment
Other: ConvaFoam dressings

Participants wounds will be assessed and will be allocated ConvaFoam Border, Silicone or Non-Adhesive dressing based upon the investigator's clinical judgment. participants will receive a dressing as part of a protocol of care for up to a period of 4 weeks

Device: ConvaFoam
ConvaFoam™ Border, ConvaFoam™ Non-Adhesive, and ConvaFoam™ Silicone dressings are designed to provide a moist wound healing environment. All participants will be assigned a dressing based upon clinical judgement for a maximum of 4 weeks with weekly assessments and dressing changes
Other Names:
  • ConvaFoam Silicone
  • ConvaFoam Border
  • ConvaFoam Non Adhesive
  • Outcome Measures

    Primary Outcome Measures

    1. Demonstrate the efficacy of ConvaFoam ™ Border, ConvaFoam™ Non-Adhesive and ConvaFoam™ Silicone to manage the indicated acute wounds when used in accordance with the IFU [4 weeks]

      The efficacy will be measured by the dressings ability to manage exudate as demonstrated by: Lack of strikethrough Maintenance or improvement of peri-wound skin

    Secondary Outcome Measures

    1. Demonstrate the performance of ConvaFoam™ Border, ConvaFoam™ Non-Adhesive and ConvaFoam™ Silicone to manage the indicated acute wounds when used in accordance with the IFU [4 weeks]

      Performance will be measured by: Wound healing as anticipated by primary or secondary intention Wear time Atraumatic removal Pain (pre application during application and on removal) Dressing comfort (patient satisfied with dressing comfort, able to resume activities of daily living) Ease of use Ease of removal Health Care Practitioner satisfaction

    2. Demonstrate the safety of, ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ Non-Adhesive dressings in the management of the indicated acute wounds when used in accordance with the IFU. [4 weeks]

      Safety will be measured by: Adverse reaction (including wound complications such as maceration, bleeding, blistering / protection of peri-wound edges / peri-wound skin integrity) Device Malfunctions

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients aged 18 years and over

    • Patients able and willing to provide informed consent

    • Patients with Surgical wounds including incisional wounds including laparoscopic

    • wounds and surgical wounds healing by secondary intention.

    • Patients with Traumatic wounds

    • Patients must be willing to attend visits as per schedule in protocol

    Exclusion criteria:
    • Patients with known allergies to any of the materials used in the dressing

    • Patients who require any oxidising agents such as hydrogen peroxide or hypochlorite solutions.

    • Patients, who in the opinion of the investigator, is considered unsuitable for any other reason

    • Patients with wounds showing signs of infection on presentation or not resolving with the use of antibiotics

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • ConvaTec Inc.

    Investigators

    • Study Chair: Kerem Ozer, MD, Medical Director

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    ConvaTec Inc.
    ClinicalTrials.gov Identifier:
    NCT05632276
    Other Study ID Numbers:
    • WC-22440
    First Posted:
    Nov 30, 2022
    Last Update Posted:
    Dec 2, 2022
    Last Verified:
    Dec 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 2, 2022